Tag Archives: ip

“Obamacare” Survives – Including Path to Generic Biologicals

Biotech patent attorneys rejoice – no matter if you represent generic companies or NDA holders,  the 5-4 decision of the Supreme Court upholding the “individual mandate” – not under the commerce clause, but as an appropriate use of Congress’ power to … Continue reading

Posted in Follow-On Biologics | Tagged , , , , , , , | Leave a comment

Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…

Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

From The EPO: Oral Proceedings/Interviews Before Examining Division Can Be Held Via Videoconferencing

This is a guest post from Lynnea Fedyk, legal process assistant at Schwegman, Lundberg & Woessner, P.A. Attached are two documents of particular interest regarding Oral Proceedings by video conference and submission of email during video conference. Should you like to … Continue reading

Posted in EP and UK Practice | Tagged , , , , , , | Leave a comment

Lather. Rinse. Repeat — In re Baxter International, Inc.

The following is a guest blog from Ron Schutz of Robins, Kaplan, Miller & Ciresi. It just got it easier for infringers to use reexamination as a way to wash a judicial patent validity determination right out of their hair. … Continue reading

Posted in Post-issuance procedures, Reexamination | Tagged , , , , , , , , , , | Leave a comment